A peak in IL-6 concentrations in patients with stage IIB, IIIA, and IIIB lung cancer, with values of 44.14 pg/mL, 47.36 pg/mL, and 37.00 pg/mL, respectively, was one of the most notable changes in biomarker concentrations in relation to lung cancer stage. This evidence concerns the gene IL6 and lung carcinoma.